Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;69(8):e29581.
doi: 10.1002/pbc.29581. Epub 2022 Mar 22.

Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001

Uma H Athale  1 , Yael Flamand  2 , Traci Blonquist  2 , Kristen E Stevenson  2 , Menachem Spira  3 , Barbara L Asselin  4 , Luis A Clavell  5 , Peter D Cole  6 , Kara M Kelly  7 , Caroline Laverdiere  8 , Jean-Marie Leclerc  8 , Bruno Michon  9 , Marshall A Schorin  10 , Jennifer J G Welch  11 , Marian H Harris  12 , Donna S Neuberg  2 , Stephen E Sallan  13 , Lewis B Silverman  13
Affiliations

Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001

Uma H Athale et al. Pediatr Blood Cancer. 2022 Aug.

Abstract

Background/objectives: Although thromboembolism (TE) is a serious complication in patients with acute lymphoblastic leukemia (ALL), thromboprophylaxis is not commonly used due to the inherent bleeding risk in this population. Identifying prothrombotic risk factors will help target thromboprophylaxis to those at highest thrombotic risk. We aimed to define predictors and the impact of TE on ALL outcome in children (1-18 years) treated on the Dana-Farber Cancer Institute ALL 05-001 trial.

Methods: Clinical and laboratory data including TE events were prospectively collected. PCR-based allelic discrimination assay identified single-nucleotide polymorphisms (SNP) for prothrombin G20210A (rs1799963) and Factor V G1691A (rs6025). Univariate and multivariable competing risk regression models evaluated the effect of diagnostic clinical (age, sex, body mass index, ALL-immunophenotype, risk group) and laboratory variables (presenting leukocyte count, blood group, SNPs) on the cumulative incidence of TE. Cox regression modeling explored the impact of TE on survival.

Results: Of 794 patients [median age 4.97 (range, 1.04-17.96) years; males 441], 100 developed TE; 25-month cumulative incidence 13.0% (95% CI, 10.7%-15.5%). Univariate analyses identified older age (≥10 years), presenting leucocyte count, T-ALL, high-risk ALL, and non-O blood group as risk factors. Age and non-O blood group were independent predictors of TE on multivariable regression; the blood group impact being most evident in patients 1-5 years of age (P = 0.011). TE did not impact survival. Induction TE was independently associated with induction failure (OR 6.45; 95% CI, 1.64-25.47; P = 0.008).

Conclusion: We recommend further evaluation of these risk factors and consideration of thromboprophylaxis for patients ≥10 years (especially those ≥15 years) when receiving asparaginase.

Keywords: ABO blood group; acute lymphoblastic leukemia; adolescents and young adults; children; predictors; thromboembolism.

PubMed Disclaimer

References

REFERENCES

    1. Tuckuviene R, Ranta S, Albertsen BK, et al. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. J Thromb Haemost. 2016;14(3):485-494. 10.1111/jth.13236.
    1. Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452-459. 10.1111/j.1365-2141.2010.08524.x.
    1. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003-re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010;149(3):410-413. https://doi.org/10.1111/j.1365-2141.2010.08132.x.
    1. Klassen ILM, Lauw MN, Fiocco M, et al. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis. Res Pract Thromb Haemost. 2019; 3:234-241.
    1. Barzilai-Birenboim S, Nirel R, Arad-Cohen N, et al. Venous thromboembolism and its risk factors in children with acute lymphoblastic leukemia in Israel: a population-based study. Cancers; 202(12): 2759-2764. 10.3390/cancers12102759.

Publication types

LinkOut - more resources